Airway doses first subject in bronchopulmonary dysplasia trial in Spain
Zelpultide alfa has received Orphan Drug Designation from the European Medicines Agency and the US FDA.
News
Latest in
News
Martis Capital invests in Alcanza Clinical Research
Alcanza is changing the model for research access to underrepresented people to enhance inclusion in clinical trials.
Enanta commences Phase IIb trial of RSV treatment
The time to RSV lower respiratory tract disease symptoms resolution is the trial’s primary endpoint.
Kezar to commence Phase IIa autoimmune hepatitis therapy trial
The Phase IIa trial will analyse the safety and efficacy of zetomipzomib in patients with AIH.
FDA grants IND clearance for Immuneering’s Phase I/IIa solid tumour trial
The trial is anticipated to begin in the fourth quarter of this year.
Zealand Pharma reports data from Phase III short bowel syndrome trial
In the trial, 65.7% of subjects in the twice-weekly glepaglutide arm had a clinically meaningful response.
Kinarus to discontinue Phase II trial of Covid-19 treatment
DSMB noted that there exists a reduced chance to demonstrate a statistically significant benefit of KIN001 in the trial.
Avidity launches Phase I/II muscular dystrophy treatment trial
The safety and tolerability of AOC 1020 in FSHD patients is the primary objective of the trial.